Transcatheter Mitral Valve Repair for Degenerative Mitral Regurgitation

Raj R. Makkar, Joanna Chikwe, Tarun Chakravarty, Qiudong Chen, Patrick T. O'Gara, Marc Gillinov, Michael J. Mack, Andrew Vekstein, Dhairya Patel, Amanda Lee Stebbins, Annetine C. Gelijns, Moody Makar, Deepak L. Bhatt, Samir Kapadia, Sreekanth Vemulapalli, Martin B. Leon

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

Importance: There are limited data on the outcomes of transcatheter edge-to-edge mitral valve repair for degenerative mitral regurgitation (MR) in a real-world setting. Objective: To evaluate the outcomes of transcatheter mitral valve repair for degenerative MR. Design, Setting, and Participants: Cohort study of consecutive patients in the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapies Registry who underwent nonemergent transcatheter mitral valve repair for degenerative MR in the US from 2014 through 2022. Exposure: Transcatheter edge-to-edge mitral valve repair with the MitraClip device (Abbott). Main Outcomes and Measures: The primary end point was MR success, defined as moderate or less residual MR and a mean mitral gradient of less than 10 mm Hg. Clinical outcomes were evaluated based on the degree of residual MR (mild or less MR or moderate MR) and mitral valve gradients (≤5 mm Hg or >5 to <10 mm Hg). Results: A total of 19088 patients with isolated moderate to severe or severe degenerative MR who underwent transcatheter mitral valve repair were analyzed (median age, 82 years; 48% women; median Society of Thoracic Surgeons predicted risk of mortality with surgical mitral valve repair, 4.6%). MR success was achieved in 88.9% of patients. At 30 days, the incidence of death was 2.7%; stroke, 1.2%; and mitral valve reintervention, 0.97%. MR success compared with an unsuccessful procedure was associated with significantly lower mortality (14.0% vs 26.7%; adjusted hazard ratio, 0.49; 95% CI, 0.42-0.56; P <.001) and heart failure readmission (8.4% vs 16.9%; adjusted hazard ratio, 0.47; 95% CI, 0.41-0.54; P <.001) at 1 year. Among patients with MR success, the lowest mortality was observed in patients who had both mild or less residual MR and mean mitral gradients of 5 mm Hg or less compared with those with an unsuccessful procedure (11.4% vs 26.7%; adjusted hazard ratio, 0.40; 95% CI, 0.34-0.47; P <.001). Conclusions and Relevance: In this registry-based study of patients with degenerative MR undergoing transcatheter mitral valve repair, the procedure was safe and resulted in successful repair in 88.9% of patients. The lowest mortality was observed in patients with mild or less residual MR and low mitral gradients..

Original languageEnglish
Pages (from-to)1778-1788
Number of pages11
JournalJAMA - Journal of the American Medical Association
Volume329
Issue number20
DOIs
StatePublished - 23 May 2023

Fingerprint

Dive into the research topics of 'Transcatheter Mitral Valve Repair for Degenerative Mitral Regurgitation'. Together they form a unique fingerprint.

Cite this